Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Clinical Laserthermia Systems publishes annual report for 2024 | 2 | Cision News | ||
27.05. | Clinical Laserthermia Systems AB: Notice of Annual General Meeting of Clinical Laserthermia Systems AB June 27, 2025 | 1 | Cision News | ||
16.05. | Clinical Laserthermia Systems AB: Clinical Laserthermia Systems AB publishes Interim report for January - March 2025 | 111 | GlobeNewswire (Europe) | Summary of the interim report (relates to the Group)Three months (01/01/2025-03/31/2025)
Net sales totaled SEK 4,496,000 (SEK 3,140,000).
Operating profit totaled SEK -7,868,000 (SEK -16,992,000).
Profit/loss... ► Artikel lesen | |
28.04. | ClearPoint Neuro, Inc.: ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism to Include 1.5 T MRI | 76 | ACCESS Newswire | SOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the... ► Artikel lesen | |
28.04. | Clinical Laserthermia Systems, together with its partner ClearPoint Neuro, announces FDA submission to expand the labeling of ClearPoint Prism® to include 1.5 T MRI guidance | 3 | Cision News | ||
15.04. | Clinical Laserthermia Systems AB: Updated clinical guidelines provide clear recommendations on the use of Laser Interstitial Thermal Therapy (LITT) in patients with metastatic brain tumors and radiation necrosis | 81 | GlobeNewswire (Europe) | Clinical Laserthermia Systems AB (publ) ("CLS or the "Company") today announces that updated clinical guidelines with recommendations supporting the use of Laser Interstitial Thermal Therapy (LITT)... ► Artikel lesen | |
08.04. | Clinical Laserthermia Systems AB: Proposed U.S. tariffs expected to have minimal impact on CLS business | 93 | GlobeNewswire (Europe) | Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or "the Company") clarifies that the proposed U.S. tariffs are expected to have minimal impact on its total business, including operations... ► Artikel lesen | |
CLINICAL LASERTHERMIA SYSTEMS Aktie jetzt für 0€ handeln | |||||
27.02. | Clinical Laserthermia Systems AB raises up to SEK 37m through a directed issue for accelerated commercialization and expansion | 1 | Cision News | ||
21.02. | Clinical Laserthermia Systems AB: Clinical Laserthermia Systems AB publishes Year-end report January - December 2024 | 156 | GlobeNewswire (Europe) | Summary of the year-end report (relates to the Group)Full year (01/01/2024-12/31/2024)
Net sales totaled SEK 18,783,000 (SEK 8,273,000).
Operating profit/loss totaled SEK -54,254,000 (SEK -65,933... ► Artikel lesen | |
07.02. | Clinical Laserthermia Systems AB: CLS co-founder and former CEO Lars-Erik Eriksson leaves the board of directors at his own request | 1.072 | GlobeNewswire (Europe) | Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that Lars-Erik Eriksson, co-founder, long-time board member and former CEO, is leaving the board of directors... ► Artikel lesen | |
30.01. | Clinical Laserthermia Systems AB: Data from the clinical trial using MRI-guided FLA with TRANBERG® Thermal Therapy System in patients with prostate cancer at Radboud University Medical Center (Nijmegen, NL) is now published | 1 | Cision News | ||
14.01. | Clinical Laserthermia Systems AB: CLS Recaps 2024 and Provides Outlook for 2025-26 | 491 | GlobeNewswire (Europe) | Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that, in its recap of 2024, in the first nine months of 2024 compared to the same period 2023, CLS saw... ► Artikel lesen | |
09.12.24 | Clinical Laserthermia Systems AB: The Nomination Committee of Clinical Laserthermia Systems AB has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on June 28, 2024. | 2 | Cision News | ||
23.10.24 | Clinical Laserthermia Systems AB: CLS focus entirely on its successful neurosurgery business positioning the company for sustainable high-margin growth with a more streamlined operation | 189 | GlobeNewswire (Europe) | Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces it will focus entirely on its successful neurosurgery business to drive sustainable high-margin growth... ► Artikel lesen | |
19.07.24 | Nasdaq Stockholm AB: New equity rights for trading, Clinical Laserthermia Systems AB TO 7 B | 436 | GlobeNewswire | At the request of Clinical Laserthermia Systems AB, Clinical Laserthermia
Systems AB equity rights will be traded on First North Growth Market as from
July 22, 2024.
Security name: Clinical Laserthermia... ► Artikel lesen | |
11.07.24 | Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Clinical Laserthermia Systems AB (Record Id 269640) | 377 | GlobeNewswire | At the request of Clinical Laserthermia Systems AB, the last trading day in
Clinical Laserthermia Systems AB's paid subscription units will be changed from
2024-07-12 to 2024-07-16.
Instrument:... ► Artikel lesen | |
11.06.24 | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Clinical Laserthermia Systems AB (Record Id 265418) | 589 | GlobeNewswire | With effect from June 12, 2024, the unit rights in Clinical Laserthermia
Systems AB will be traded on First North Growth Market. Trading will continue
up until and including June 20, 2024.
Instrument:... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SIEMENS HEALTHINEERS | 46,650 | +0,26 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
FRESENIUS | 44,290 | +0,11 % | DAX-Check LIVE: Bilfinger, Cancom, Delivery Hero, Fresenius, Gerresheimer, Rheinmetall im Fokus | Der DAX hat den gestrigen Handelstag mit leichten Verlusten beendet. Der deutsche Leitindex schloss 0,28 Prozent tiefer bei 23.930 Punkten. Zwar konnte er sich am Nachmittag vom Tagestief bei 23.740... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 50,32 | -0,40 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für FMC mit einem Kursziel von 41,50 Euro auf "Underweight" belassen. Die Anleger warteten auf neue Mittelfristziele und Neuigkeiten... ► Artikel lesen | |
GERRESHEIMER | 47,800 | -2,73 % | EQS-Adhoc: Gerresheimer AG: Anpassung der Prognose für 2025 | EQS-Ad-hoc: Gerresheimer AG / Schlagwort(e): Prognoseänderung/Dividende
Gerresheimer AG: Anpassung der Prognose für 2025
02.06.2025 / 11:40 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
PROCEPT BIOROBOTICS | 62,91 | -3,29 % | Procept Biorobotics auf Jefferies-Konferenz: Strategische Innovationen in der BPH-Behandlung | ||
OMADA HEALTH | 23,000 | 0,00 % | Omada Health Announces Pricing of Initial Public Offering | SAN FRANCISCO--(BUSINESS WIRE)--Omada Health, the virtual between-visit healthcare provider, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock, at a... ► Artikel lesen | |
CARL ZEISS MEDITEC | 60,10 | +1,43 % | Carl Zeiss Meditec - Günstig bewertet; Foerst muss es jetzt richten | In den beiden ersten Teilen unserer Serie zu Carl Zeiss Meditec haben wir die jüngsten Führungswechsel und die kurzzeitigen Hemmnisse im Geschäftsmodell beleuchtet. Im dritten Teil prüfen wir, ob die... ► Artikel lesen | |
PRIVIA HEALTH GROUP | 23,190 | +1,71 % | Privia Health Group, Inc.: Privia Health Reports First Quarter 2025 Financial Results | Strong First Quarter Performance and Operating ExecutionEnters the State of ArizonaFull-Year 2025 Outlook Raised to Mid- to High End of Guidance Ranges for All Metrics with Attributed Lives Unchanged... ► Artikel lesen | |
UNITEDHEALTH | 266,05 | 0,00 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: UnitedHealth, Flatexdegiro und Friedrich Vorwerk! | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 10:00 Uhr, Deutschland: Friedrich... ► Artikel lesen | |
HIMS & HERS HEALTH | 48,990 | -0,97 % | US-Telemedizin-Anbieter: Hims & Hers expandiert nach Europa: Zava bringt Millionen neue Nutzer! | © Foto: SOPA Images - Sipa USAHims & Hers übernimmt die europäische Telemedizin-Plattform Zava und wächst dadurch um 1,3 Millionen Nutzer. Die Aktie legt daraufhin im vorbörslichen Handel an der Nasdaq... ► Artikel lesen | |
ECKERT & ZIEGLER | 65,05 | -3,49 % | Eckert&Ziegler-Aktie leicht im Plus (62,55 €) | Der Anteilsschein von Eckert&Ziegler notiert am Montag etwas fester. Der jüngste Kurs betrug 62,55 Euro. Freuen können sich gegenwärtig die Aktionäre von Eckert&Ziegler: Die Aktie weist gegenwärtig... ► Artikel lesen | |
DRAEGERWERK | 71,60 | +2,14 % | EQS-News: Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 der Verordnung (EU) Nr. 596/2014 i.V.m. Art. 2 Abs. 1 der Delegierten Verordnung (EU) 2016/1052 der Kommission | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Sonstiges
Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 der Verordnung (EU) Nr. 596/2014 i.V.m. Art. 2 Abs. 1... ► Artikel lesen | |
BRIGHTSPRING HEALTH SERVICES | 24,105 | +2,57 % | BrightSpring's Care Ratings Climb: Is Its Lead Sustainable? | ||
MIMEDX | 6,490 | +2,37 % | MiMedx Group, Inc: MIMEDX Announces First Quarter 2025 Operating and Financial Results | Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA... ► Artikel lesen | |
NUTEX HEALTH | 122,40 | -0,81 % | Nutex Health, Inc.: Nutex Health Reports First Quarter 2025 Financial Results | TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8%
NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET... ► Artikel lesen |